NCT02592356View on ClinicalTrials.gov

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 16, 2015

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2024

Conditions

Differentiated Thyroid Gland CarcinomaMalignant Adrenal Gland PheochromocytomaMalignant ParagangliomaThyroid Gland Medullary Carcinoma

Interventions

PROCEDURE

Computed Tomography

Correlative studies

PROCEDURE

Dual X-ray Absorptiometry

Correlative studies

PROCEDURE

Physical Examination

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Cabozantinib

DRUG

Lenvatinib

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02592356 - Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer | Biotech Hunter | Biotech Hunter